Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Mehr anzeigen
Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.2196 | 12.5485714286 | 1.75 | 1.9698 | 1.74 | 117703 | 1.89377761 | CS |
| 4 | 0.1696 | 9.42222222222 | 1.8 | 2.45 | 1.65 | 182493 | 1.91791173 | CS |
| 12 | 1.2596 | 177.408450704 | 0.71 | 2.45 | 0.69 | 632089 | 1.45067577 | CS |
| 26 | 1.2696 | 181.371428571 | 0.7 | 2.45 | 0.5116 | 366345 | 1.26665744 | CS |
| 52 | 0.9596 | 95.0099009901 | 1.01 | 2.45 | 0.5116 | 229035 | 1.22100724 | CS |
| 156 | -10.6504 | -84.3930269414 | 12.62 | 13.7 | 0.5116 | 463482 | 2.27840959 | CS |
| 260 | -50.0804 | -96.2159462056 | 52.05 | 121.98 | 0.5116 | 458026 | 13.36289313 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
